Reata Pharmaceuticals Other Liabilities

Reata Pharmaceuticals (RETA) currently reports a other liabilities of $0 as of June 2023. That compares with $380M in the prior-year period — down 100.0% year over year. Use the charts on this page to explore Reata Pharmaceuticals's other liabilities history and peer comparisons.

Reata Pharmaceuticals's other liabilities decreased from $380M to $0 — a 100.0% year-over-year decrease (period ending June 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Reata Pharmaceuticals reported $0 in other liabilities as of June 2023. That compares with $380M in the prior-year period — down 100.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other liabilities of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Reata Pharmaceuticals, and consider following RETA for alerts when major investors trade the stock.

Reata Pharmaceuticals is classified in the Healthcare sector. On other liabilities, it currently shows $0. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing RETA with unrelated industries.